William Blair Investment Management 13F: Adds $53M to HALO Stake

William Blair Investment Management has boosted its stake in Halozyme Therapeutics, Inc. (NasdaqGS: HALO) by 37.1%, according to its latest Form 13F filing with the SEC. The firm added 683,019 shares, bringing its total holdings to 2,525,975 shares, valued at approximately $194.95 million as of the reporting period.

What Changed in William Blair Investment Management's Halozyme Therapeutics Position

William Blair Investment Management significantly increased its investment in Halozyme Therapeutics during the latest quarter. The firm added 683,019 shares, growing its holdings by 37.1% to a total of 2,525,975 shares. This substantial increase highlights the firm's confidence in the company's future prospects.

Other Institutional Activity in Halozyme Therapeutics

Several other institutional investors also made changes to their positions in Halozyme Therapeutics. BlackRock, Inc. increased its holdings by 111,196 shares, ending with 13,265,053 shares valued at about $857.32 million, representing a modest 0.8% increase. Vanguard Capital Management LLC opened a new position with 5,271,218 shares worth approximately $340.68 million. Similarly, Vanguard Portfolio Management LLC initiated a new stake with 5,249,206 shares, valued at $339.26 million. State Street Corp reduced its holdings by 183,818 shares, resulting in a 3.6% decrease, with a total of 4,937,854 shares valued at $319.13 million. Invesco Ltd. added 364,431 shares, growing its stake by 10% to 4,012,494 shares, worth about $259.33 million.

Halozyme Therapeutics, Inc. Stock Down 35.6%

Shares of Halozyme Therapeutics traded near $77.18 on Tuesday. The company has a market capitalization of $8.89 billion and a P/E ratio of 26.3, with a forward P/E of 7.58. Its beta is 0.869, suggesting lower volatility compared to the market. The stock's 52-week range is between $51.06 and $82.22. The 50-day moving average stands at $68.26, while the 200-day moving average is $69.08. The company maintains a current ratio of 2.76 and a quick ratio of 2.14, though it has a relatively high debt-to-equity ratio of 991.21.

Recent Earnings

In its most recent earnings report, Halozyme Therapeutics posted revenue of approximately $1.51 billion, reflecting a growth of 42.2%. The company's net margin was 23.13%, with a return on equity of 99.4%. The next earnings release is scheduled for August 4, 2026.

Insider Buying and Selling at Halozyme Therapeutics, Inc.

Recent insider activity at Halozyme Therapeutics included several transactions by SVP and Chief Legal Officer Mark Howard Snyder, who sold 5,034 shares on June 12, 2026, without a specified price. On the same day, Snyder sold 2,715 shares at $69.50 each. President and CEO Helen Torley also reported significant transactions, buying 10,000 shares at $12.07 on June 3, 2026, and selling 10,000 shares at $69.07, which was a planned transaction.

Analysts Set New Price Targets

On May 12, 2026, Morgan Stanley maintained its 'buy' rating for Halozyme Therapeutics, setting a price target of $93.00. Earlier, on April 29, 2026, HC Wainwright & Co. also maintained a 'buy' rating with a target of $95.00. The consensus among analysts is a 'buy' recommendation, with a mean target price of $83.90 based on 10 analyst opinions.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc. is a biotechnology company based in San Diego, California. It focuses on researching, developing, and commercializing proprietary enzymes and devices that enhance the delivery of injectable biologics and other therapeutic molecules. The company's flagship product is the recombinant human hyaluronidase enzyme (rHuPH20), which improves the dispersion and absorption of injected drugs. Halozyme collaborates with several global pharmaceutical companies, including Roche, Pfizer, and Janssen Biotech.

Bottom Line

William Blair Investment Management's significant increase in its stake in Halozyme Therapeutics reflects a strong vote of confidence in the company's potential. While 13F filings are backward-looking and may not represent the most current positions, they offer valuable insights into institutional investment strategies. Investors and analysts will continue to monitor Halozyme's performance and strategic developments closely.